(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 37.41% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.8%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.45%.
Harrow's revenue in 2026 is $275,594,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $13,324,681,404, with the lowest HROW revenue forecast at $12,597,417,114, and the highest HROW revenue forecast at $13,879,126,706. On average, 10 Wall Street analysts forecast HROW's revenue for 2027 to be $19,786,462,109, with the lowest HROW revenue forecast at $17,340,379,896, and the highest HROW revenue forecast at $22,692,520,241.
In 2028, HROW is forecast to generate $27,027,240,336 in revenue, with the lowest revenue forecast at $23,779,293,012 and the highest revenue forecast at $30,928,226,007.